Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group (Q51552529)
Jump to navigation
Jump to search
scientific article published in November 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group |
scientific article published in November 2000 |
Statements
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group (English)
1 reference
Aronoff S
1 reference
Rosenblatt S
1 reference
Braithwaite S
1 reference
Egan JW
1 reference
Mathisen AL
1 reference
Schneider RL
1 reference
1 November 2000
1 reference
23
1 reference
11
1 reference
1605-1611
1 reference